Individualized treatment with denosumab in children with osteogenesis imperfecta – follow up of a trial cohort

BACKGROUND: Osteogenesis imperfecta (OI) is a rare disease leading to hereditary bone fragility. Nearly 90% of cases are caused by mutations in the collagen genes COL1A1/A2 (classical OI) leading to multiple fractures, scoliosis, short stature and nonskeletal findings as blue sclera, hypermobility o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoyer-Kuhn, Heike, Rehberg, Mirko, Netzer, Christian, Schoenau, Eckhard, Semler, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751648/
https://www.ncbi.nlm.nih.gov/pubmed/31533771
http://dx.doi.org/10.1186/s13023-019-1197-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751648/
https://www.ncbi.nlm.nih.gov/pubmed/31533771
http://dx.doi.org/10.1186/s13023-019-1197-z

Ejemplares similares